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PART A: THE PROTOCOL 
 
















List of Abbreviations 
DEBM  - Donated Expressed Breast Milk 
EBM  - Expressed breast milk 
ELBW  - Extremely low birth weight 
GV  - Growth Velocity 
HIV  - Human Immunodeficiency Virus 
IVF  - Intravenous Fluids 
NEC  - Necrotising Enterocololitis 
NVD  - Normal Vaginal Delivery 
PT  - Preterm 
PVL  - Periventricular Leucomalacia 
UAC  - Umbilical Arterial Catheter 
USA  - United States of America 
















Purpose of the study 
Primary objective 
To describe the growth velocity of extremely low birth weight babies seen at Groote Schuur 
Hospital nursery and to compare this to growth velocities of similar babies in published 
literature. 
Background 
Extremely low birth weight preterms are increasingly surviving in recent times due to advances 
in care and more availability and use of surfactant. These babies present the neonatologists with 
new feeding and growth challenges due to the extreme prematurity of their various body 
systems. In utero, the fetus gets its nutrition from the mother via the umbilical vessels. However, 
the fetus does swallow large amounts of amniotic fluid which is thought to provide proteins and 
hormones which stimulate gut growth. The intrauterine growth velocity decreases from 
approximately 21 g/kg/d between 23 and 27 weeks‘ gestation to 12 g/kg/d between 35 and 37 
weeks‘ gestation. The average growth velocity for the entire period from 23 to 37 weeks‘ 
gestation is approximately 16 g/kg/d.[1] Our aim in feeding the preterm is to mimic these growth 
rates. This is a great challenge. The preterm fetus has diminished glycogen stores compared to its 
term counterpart due to the interruption in the laying down of these glycogen stores – a process 
that takes place in the third trimester. Similarly, the preterm has diminished fat stores with 2% of 
its body weight as fat compared to its term counterpart who has 15% of its body weight as fat.[2] 
With an increased metabolic rate, worsened by morbidities, and coupled with an immature gut – 















nutrition. Many researchers hold the opinion that faced with these challenges, growth restriction 
at 36 weeks post menstrual age is an inevitable consequence in these ELBW preterm babies.[3] 
Growth can be monitored adequately in these babies by anthropometry - the measurement of 
body weight, length, head circumference, and, to a lesser extent, skin fold and arm 
circumference. Weight is a good indicator of total body composition. It however fluctuates in the 
short term with hydration status and contraction of the total water compartment postnatally.  Due 
to its ease of measure, it still offers us the best tool to monitor growth in our babies. The initial 
weight loss reaches its nadir at around the fourth to the sixth day of life[4,5] Once birth weight is 
regained, subsequent weight gain of 10 to 20 g/d for infants  less than 27 weeks GA and 20 to 30 
g/d for infants older than 27 weeks GA is desired. Weight gain is evaluated weekly and 
expressed relative to current body weight (g/kg/d), with ideal relative weight gains ranging 
between 10 and 20 g/kg/d. 
Length on the other hand is more reliable as it is seldom influenced by variations in hydration 
status. It represents an increase in the lean tissue mass. It is a better indicator of long term 
growth. However, it is more difficult to take as it requires two operators and is more prone to 
errors. Ideally, the length should be measured weekly to the nearest 0.1cm. The expected 
incremental gain in the crown – heel length is 0.9cm per week.[4] 
Increase in the head circumference usually correlates well with the overall growth of the 
neonates and their long term neurodevelopmental outcomes.[6] There may be an initial reduction 
in the head circumference of the very preterm infants in the first week of life correlating with 















Assessing the weight for length in a particular preterm helps in determining ideal weight for 
length and asymmetry in growth. It is known that infants with symmetrical intrauterine growth 
restriction will have increased morbidity compared to their asymmetrical counterparts.[6]  
Many postnatal growth charts have been developed to assess the growth trends of VLBW 
preterms.[3-5] With improvement in feeding strategies, the subsequent growth curves show less 
and less time to achieve birth weight after the initial fall in weight with a lesser percentage loss 
in weight in these preterms. It was previously thought to be acceptable and expected for extreme 
low birth weight preterms to lose up to 20% of their birth weight and to take up to 3 weeks to 
regain birth weight – a phenomenon less frequently seen in more recent growth charts.[5] 
Study Justification 
The current published data on growth velocities from the developed world reflect the ―ideal‖ 
growth in preterms in those particular populations. Growth is tightly linked to the feeding 
practices in our nurseries plus the obvious influences of genetics and the environment. Different 
nurseries have different feeding protocols. Unlike in the developed world where there is frequent 
use of parenteral nutrition, our feeding protocol places emphasis on early human breast milk 
feeding with supplemented intravenous fluids prior to achieving full enteral feeds. This study 
will enable us compare the growth velocity of our ELBW preterms in our resource constrained 

















The study will be conducted at Groote Schuur Hospital nursery. This is a tertiary neonatal unit 
with a 75 bed capacity – 20 ICU and high care beds, 25 medium care beds and 30 general ward 
beds. The unit admits around 2000 babies every year with slightly less than 200 of these babies 
weighing less than 1000g. Almost half of these babies are born with intrauterine growth 
restriction. This could be attributed to the fact that being a tertiary referral centre, the maternity 
unit receives a high number of pregnancies complicated with hypertension leading to majority of 
the preterm deliveries. We know from unpublished data that around 16% of the mothers 
delivering in our maternity are HIV positive and our current rate of mother to child transmission 
of HIV with our current preventative strategy is less than 1%.(Harisson MC, Department of 
Neonatal Medicine, University of Cape Town 2011) 
Study design 
This will be a retrospective cohort study. Patients weighing less than 1000g will be 
identified from a prospectively collected database. Files of babies born during the 6 
month study period, that is from 1
st
 March 2010 to 31
st
 August 2010, will be retrieved 
and relevant data extracted. 
Characteristics of study population 
These are babies that were born with a birth weight of less than 1000g during the study period, 















Recruitment and Enrolment 
All files of babies born with a birth weight of less than 1000g during the study period will be 
retrieved and reviewed to asses if the baby met the study‘s eligibility criteria. All eligible babies 
will be enrolled into the study. 
Eligibility Criteria 
 Birth weight of less than 1000g 
 Survived to discharge 
Exclusion Criteria 
 Major congenital malformations 
 Grade 3 or 4 IVH, hydrocephalus or PVL  
 NEC (Bell‘s grade II or worse) 
 Babies who require withholding of enteral feeds for more than 3 days, whatever 
the reason. 
Research procedures and Data collection methods 
Weight measurements 
Babies in our unit are weighed between 5am and 6am everyday when in the ICU, high care and 
medium care units, and three times weekly (on Mondays, Wednesdays and Fridays) in the 
general wards. All babies are weighed naked on digital weighing machines that are routinely 
calibrated by our full time technicians in the unit. Weighing is usually skipped for the very 















are more stable. Any unusual discrepancies noted on the weight trend, for example unusual gains 
or losses are usually confirmed by a repeat weighing. 
For our study, weekly weights will be retrieved from the weight charts in the folders and any 
missing weight will be gotten from the average of the immediate weight before and after the 
weight in question. 
Head Circumference 
All newborns in our unit routinely have their birth and discharge head circumference plotted on 
the infant‘s growth chart. For our study, these figures will be retrieved from the growth chart in 
the infant folder. 
Feeding practice 
Feeding of neonates in our unit follows a strict protocol as described in a copy attached hitherto 
(appendix 1). 
Gestational Age estimation 
The gestational age will be extrapolated from an ultrasound report done at < 20 weeks gestation 
and where this is not available, the Ballard score from the infant records will be used.  
Growth velocity calculation 
Growth velocity will be determined from the weekly weights starting from day seven (as 
at this point, weight loss usually has reached its nadir), using the two point system (6) as 
shown below: 
















W – weight in grams, D – day, 1 –beginning of time interval, n – end of time interval in 
days. 
The calculated weekly growth velocities for the first 8 weeks or to discharge (whichever 
comes first) will be averaged to give the mean growth velocity of the individual baby. 
Increase in head circumference was determined by dividing the gain on the head 
circumference at discharge from that at birth by the duration of stay in weeks. 
Data Collection 
Data will be collected by reviewing the babies‘ medical records and recorded onto a data 
sheet (see appendix 2). 
 
The following information will be sought: 
 Date of birth 
 Birth weight 
 Gestation at birth 
 Head circumference at birth 
 Whether antenatal steroids were given or not 
 HIV exposure (mum‘s HIV status) 
 Weekly weights for the first 8 weeks or till discharge (whichever comes first) 















 Number of days to achieving full feeds 
 Number of days to regaining birth weight 
 Discharge head circumference 
 Weight at discharge 
 Number of days admitted 
Data Analysis 
The information will subsequently be transferred onto an excel spreadsheet, and then 
transferred to STATA for analysis. Data will be explored for distribution, baseline 
characteristics of the study population will be sought and measures of association 
between the different variables will be undertaken.  
Study definitions 
 Full enteral feeds will be defined as total enteral feeds of 150ml/kg/day. 
 Time to regain birth weight will be defined as the day birth weight is achieved 
and sustained (or exceeded) for two consecutive days.  
 Predominant feed will be taken as the type of feed given more than half the times 
in the first four weeks of life. 
 Where a particular weight to be recorded was missing, the average of the 
immediate weight before and after the sought weight will be taken as 
representative. 
 Small for gestational age babies were babies that fell below the 10th percentile for 















Biases and quality assurance  
 Weights are always taken at around the same time of the night 
 Accuracy of the weighing scales in the unit is regularly checked and confirmed by 
the technicians 
 Babies in the unit are routinely weighed without any clothes on 
Study Limitations 
Use of retrospective data decreases certainty of our measurements 
Data safety and Monitoring 
The data sheets will be maintained in a locked cabinet in the department of Neonatal Medicine 
offices. The data in the computer is anonymous keeping patient confidentiality and access will be 
password protected. 
Description of Risks and Benefits 
There are no foreseeable risks to the patients in this study as there will be no contact with the 
patients given the retrospective nature of this folder review study. Results of this study may 
benefit our future patients as comparison of our data with the rest of the world may subsequently 















Informed consent process 
This study will not require individual consents from the parents and guardians of the study 
infants given the nature of the study. The study has been approved by the University of Cape 
Town Human Research Ethics Committee. 
Privacy and confidentiality 
Privacy and confidentiality shall be maintained throughout the study as there shall be no record 
of any identifiable information like name or folder numbers of the patients right from recruitment 
to analysis and results presentation. 
Reimbursement for Participation 
There shall be no reimbursement to any of the study participants for taking part in this study. 
Emergency care and insurance for research – related Injuries 
This is not applicable for this study. 
What happens at the end of the study? 
Results of the study will be made available to faculty members and will be published in a peer 
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Feeding Protocol For Extremely Low Birth Weight Infants At Groote Schuur Hospital 
Nursery 
Intravenous fluids are started on day 1 as shown below: 
Category Fluid type Day 1 (ml/kg/day) Glucose (mg/kg/min) 
<800g 5% Dextrose 100 3.5 
800 – 1200 10% Dextrose 90 6.25 
 
Enteral feeds are usually started on day 2 of life unless the infant is very unstable. It usually 
takes about a day to get the mothers settled post caesarean section or just settled in the wards for 
those who delivered NVD and generally it‘s the kind of duration it will take to have the doctors 
counsel the mothers on breastfeeding and obtain consent for use of donated breast milk. Thus, 
enteral feeds usually are prescribed, available and running by the second day of life. The feeds 
are usually increased by 20mls-35mls/kg everyday. The corresponding intravenous fluids are 
decreased appropriately to fit into the prescribed total fluid intake for the day as shown below: 
FEED/IVF DAY 
 1 2 3 4 5 6 7 
Total Fluid 90 100 130 150 150 150 150 
IVF 2.6-3.7 2-3mls/hr 2.7-4.4 3.3-5.2 2.2-4.2 1.2-3.2 - 
FEEDS NIL/1mlx6 1mls/hr 2mls/h 3mls/hr 4mls/hr 5mls/hr 6mls/hr 
 
Once the baby is off intravenous fluids, enteral feeds are increased at the same rate till a total 















feeds. The fluid is switched to 10% Neonatalyte or  5% Paediatric infants maintenance solution 
(for hyperglycaemic infants) after 48 hours.  
Total perenteral nutrition is initiated if there is a reason to keep baby nil by mouth for more than 
3 days.  
The contents of the fluids used as shown on the container are given below: 
 SABAX® Neonatolyte  
Per 1000mls 
SABAX® PMS  
Per 1000mls 
Glucose monohydrate 110.00g 55.00g 
Potassium Chloride 1.12g 0.89g 
Calcium Chloride Dihydrate 376mg  
Magnesium Chloride Hexahydrate 102mg  
Sodium Lactate 2.24g  
Phosphoric Acid 376mg  
Sodium Chloride  2.05 
Approximate millimoles   
Sodium 20 35 
Potassium 15 12 
Calcium 2.5  
Magnesium 0.5  
Chloride 21 47 
Lactate 20  
Phosphate (as HPO4
-
) 3.75  
Hypertonic approximate milliosmoles 645 372 
Approximate pH 4.2 4.0 
 
Enteral feeds 
The enteral feeds used in order of preference are: 
1. Mother‘s own breast milk (fresh or pasteurized as is the case with HIV positive mothers) 
2. Donated breast milk (pasteurized breast milk from screened donor mothers) 















Contents of the breast milk fortifier - FM85® and Kiddivit® multivitamin drops as given on the 
packet inserts are shown below: 
 Contents per 7.5g of FM85 Contents per 0.6 mls of 
kiddivits multivitamin drops 
Vit A (I.U) 750 3000 
Vit D (I.U) 150 400 
Vit E (I.U) 4.5  
Vit K (µg) 6  
Vit C (mg) 15 50 
Thiamine (B1) (mg) 0.075 1.5 
Riboflavin (B2) (mg) 0.15 1.2 
Niacin (B3) (mg NE) 1.2 10 
Folic acid (µg) 60  
Vit B6 (mg) 0.075 0.5 
Fat (g) 0.3  
Protein (Whey) (g) 1.5  
Carbohydrate (g) 5.03  
Energy (kcal) 27  
Calcium (mg) 112.5  
Phosphorus (mg) 67.5  
Magnesium (mg) 3.6  
Sodium (mg) 30  
Potassium (mg) 63  
Chloride (mg) 25.5  
Iron (mg) 1.95  




 On attainment of full feeds, those on breast milk feeds have their feeds fortified with 
FM85 (Nestlé Nutrition) and receive additional multivitamin drops. 
 All infants less than 32 weeks corrected gestation receive additional oral supplementation 















 Iron is given to all infants as from 2 weeks at 2-4mg/kg/day to discharge. 
 Oral phosphate at 0.5 to 1 mmol is added from 4 to 6 weeks depending on serum calcium, 




















Appendix 2 - Sample Data Capture Sheet 
ID DOB SEX GEST GR HIV HC1 HC2 BWT WT1 WT2 WT3 WT4 WT5 WT6 WT7 WT8 DA DWT DBW DFF 
                     
 
KEY 
ID Study identification number   
DOB Date of birth 
SEX Gender 
GEST Gestation at birth 
GR Growth restriction 
HIV  HIV exposure status 
HC1 Head circumference at birth 
HC 2 Head Circumference at discharge 
BWT Birth weight 
WT1 – WT8 Weight at end if week 1,  week2, week3 , etc 
DA Age at discharge in days 
DW  Weight at discharge 
DBW Days to regaining birth weight 








































OBJECTIVES OF THE LITERATURE SEARCH AND REVIEW 
The objective of the literature search and review in this study was to 
 Summarize published literature on growth monitoring strategies, growth patterns and 
growth velocity of extremely low birth weight preterm babies 
 Summarize literature on current feeding practices and controversies surrounding the 
extremely low birth weight preterm baby 
 Summarize the current recommendations on feeding and growth of the extremely low 
birth weight preterm baby 
 
LITERATURE SEARCH STRATEGY 
A comprehensive literature search was undertaken by searching MEDLINE through PUBMED 
(1975 – Feb 2011) and the Cochrane library. The key words used were: growth velocity; growth 
patterns; enteral nutrition and parenteral nutrition. The search was limited to infants of 0 to 24 
months and articles in the English language. 
Standard text books of Neonatology and Gastroenterology were also referred to. Relevant 
references quoted in these text books and the already accessed journal articles were also referred 
to for additional information. The articles finally quoted in this review are those found to be most 


















It has been observed the world over that extremely low birth weight (ELBW) preterm babies are 
increasingly surviving thanks to advances in perinatal and neonatal care.[1,2] The growing 
challenge has been to ensure optimal growth by implementing feeding strategies that address 
delivery of optimal calories and proteins at the same time keeping feeding associated morbidities 
to the minimum. The trend in practice is to aim for early and aggressive use of parenteral 
nutrition with early introduction of proteins, and early initiation of enteral feeds. Our practice 
involves early initiation of enteral feeds with expressed breast milk where feasible, and 
concomitant use of intravenous dextrose enriched with electrolytes in place of parenteral 
nutrition in most cases. Parenteral nutrition is reserved to neonates who have been kept off 
enteral feeds for more than three days for one reason or the other. Our judicious use of parenteral 
nutrition is guided by resource constraints and fear of infection given the relative overcrowding 
in our unit.  
It is now well established that early nutrition has a great influence on long term neurocognitive 
outcomes.[3-9] Ehrenkranz and colleagues recently demonstrated the dangers of poor growth in 
their study which clearly demonstrated the association between growth velocity and 
neurodevelopmental outcomes at 18 – 22 months corrected age for these ELBW preterm 
babies.[9] In their cohort of 490 ELBW infants, they found that as the rate of weight gain 
increased, the incidence of cerebral palsy (CP), mental developmental index (MDI) and 
psychomotor developmental index (PDI) scores <70, abnormal neurologic examination, and 















Similar findings were observed as the rate of head circumference growth increased. Latal-Hajnal 
and coworkers[7] also demonstrated the importance of postnatal growth in their study in which 
small for gestational age (SGA) children who showed substantial catch-up growth with weight 
above the 10th percentile at 2 years of age, had neurodevelopmental outcomes comparable to 
appropriate for gestational age (AGA) children whose weight remained appropriate for age, 
whereas SGA children who remained below the 10th percentile by age 2 were impaired in their 
motor development. In this study of VLBW children, postnatal growth pattern rather than SGA 
status, was found to be significantly associated with adverse neurodevelopmental outcome at 2 
years of age. 
Following previous feeding strategies, extra uterine growth restriction was a common 
phenomenon in many of these published works.[3-9] This primarily arose from an accumulating 
protein and calorie deficit from the first weeks of life as demonstrated by Embleton et al.[10]The 
greatest influences on the growth velocity of these babies as shown by Olsen at al[11] has been 
the protein and caloric intakes. Stephens and colleagues went further to demonstrate that what 
we feed these babies as early as the first week of life influences the neurodevelopmental 
outcomes at 18 months corrected age.[12] 
Monitoring Growth 
Growth can be monitored adequately in these babies by anthropometry - the measurement of 
body weight, length, head circumference, and, to a lesser extent, skin fold and arm 
circumference. Weight is a good indicator of total body composition. It however fluctuates in the 
short term with hydration status and contraction of the total water compartment postnatally.  Due 















weight loss reaches its nadir at around the fourth to the sixth day of life.[3,13] Once birth weight 
is regained, subsequent weight gain of 10 to 20 g/d for infants  less than 27 weeks GA and 20 to 
30 g/d for infants older than 27 weeks GA is desired. Weight gain is evaluated weekly and 
expressed relative to current body weight (g/kg/d), with ideal relative weight gains ranging 
between 10 and 20 g/kg/d to mimic intrauterine growth rates.[14,15] 
Length on the other hand is more reliable as it is seldom influenced by variations in hydration 
status. It represents an increase in the lean tissue mass. It is a better indicator of long term 
growth. However, it is more difficult to take as it requires two operators and is more prone to 
errors. Ideally, the length should be measured weekly to the nearest 0.1cm. The expected 
incremental gain in the crown – heel length is around 0.9cm per week. Increase in the head 
circumference usually correlates well with the overall growth of the neonates and their long term 
neurodevelopmental outcomes.[9] There may be an initial reduction in the head circumference of 
the very preterm infants in the first week of life correlating with receding edema. Thereafter, a 
weekly increment of around 0.9cm per week is considered adequate.[3] 
 
Assessing the weight for length in a particular preterm helps in determining ideal weight for 
length and asymmetry in growth. It is known that infants with symmetrical intrauterine growth 
restriction will suffer more morbidity compared to their asymmetrical counterparts. Many 
postnatal growth charts have been developed to assess the growth trends of VLBW 
preterms.[3,13,16] With improvement in feeding strategies, the subsequent growth curves show 
less and less time to achieve birth weight after the initial fall in weight with a lesser percentage 
loss in weight in these preterms. It was previously thought to be acceptable and expected for 















weeks to regain birth weight – a phenomenon less commonly seen in more recent growth 
charts.[13] 
 
Nutritional assessment can also be made by doing whole body composition analysis. This can be 
done using Dual-energy x-ray absorptiometry (DXA) which measures lean and fat mass and 
bone mineral content. The other methods that can be used to assess body composition include air 
displacement plethsymography (ADP), total body electrical conductivity (TOBEC), and 
bioelectrical impedance (BIA). 
 
Laboratory measurements 
Many markers have been identified and used to monitor infants as indicators of nutritional status, 
but none is without problems as they are all affected by other factors like disease status, 
infection, intake, hydration status etc. Blood urea Nitrogen (BUN), a byproduct of protein 
degradation has been used to monitor adequacy of protein intake in the past. Its level however is 
influenced by hydration status. Prealbumin and retinol-binding protein (RBP) concentrations 
appear to correlate better with nitrogen balance during nutrition therapy and have been shown to 
be a more sensitive measure of protein and calorie intake in small premature infants.[17] 
 
Calculating growth velocity 
Actual growth velocity is calculated by the formula 
GV = [(Wn+1 – Wn) X 1000] 















Where Wn= weight in grams on day ―n‖ and Wn+1= weight in grams on the following day. Daily 
changes in the growth velocity are calculated and the average growth velocity for the duration in 
question is then reported in g/kg/day. This is a laborious endeavor, which has led to simpler 
mathematical methods for estimating growth velocity to be developed. These are 2-point models 
using the difference between weights at 2 time points divided by time and weight (either birth 
weight or average weight), linear regression models that are normalized for either birth weight or 
average weight, and an exponential model. 
The two point average weight model‘s formula: 
 GV  =          1000 X (Wn – W1)   
   {[(Dn – D1)] X [(Wn + W1)/2]}     
Where W=weight in grams, D= day, 1=beginning of time interval and n=end of time interval in 
days. 
The Exponential Model‘s formula: 
GV = [1000 x ln(Wn/W1)]/(Dn-D1) 
The linear regression model formula: 
Linear birth weight (BW) model: linear regression of weight (in grams) versus time (in days), 
where  
GV  = [1000 X  (slope of regression line)/BW] 
Or 
Linear average weight model: 















GV  = [1000 X  (slope of regression line)]/[(W1 _ Wn)/2] 
 
These formulas have been compared to the actual growth velocity and their accuracy 
tested.[18,19] In these comparisons, it was noted that the exponential method was most accurate, 
being influenced minimally by increase in the duration of stay or by decrease in birth weight, 
having mean absolute errors of 0.02% to 0.10% in comparison to the true growth velocity. The 
2-point and linear models were highly inaccurate when birth weight was used in the 
denominator, with mean absolute errors of 50.3% to 96.4%. The 2-point and linear models were 
fairly accurate when average weight was used in the denominator, with mean absolute errors of 
0.1% to 8.97% . These two latter methods were however highly influenced by increasing 
duration of stay and birth weight. 
Feeding the ELBW preterm baby 
As eluded to earlier, studies have well established the fact that the greatest influence on the 
growth velocity of these ELBW preterm babies is their protein and caloric intake.[11] Because of 
their gut immaturity and associated enzyme and hormone inactivity, these babies are never put 
on full enteral feeds from the first day of life. In fact, until recently, neonatologists have been 
extremely cautious in initiating and advancing enteral feeds taking up to 21 days to the 
establishment of full enteral feeds.[3-9] Inevitably, growth charts from these old studies show a 
longer duration to achieving birth weight after the initial drop with a corresponding greater 
percentage loss of birth weight. It is well established that ELBW infants who receive glucose 
alone lose approximately 1.2 g/kg per day of protein, corresponding to a daily loss of 1% to 2% 















babies as early as the first week of life influences their neurodevelopmental outcomes at 18 
months corrected age.[12] This information has triggered increased interest in the administration 
of proteins (amino acids) early after delivery as studies have shown that administration at rates of 
3g – 3.5g/kg/day is both safe and associated with better postnatal weight gain and head 
circumference growth. Supplementation at these rates lead to intrauterine protein accretion and 
plasma amino acid levels close to those achieved in intrauterine life.[20]  
 
In the recent past, there has been more and more interest in early initiation of breast milk feeds to 
preterm babies. Excitement reigns as to the protective effects of breast milk and its short and 
long term benefit to the preterms – including, but not limited to gut priming, promotion of 
physiological and endocrine functions of the gut, better long term neurodevelopment, better 
visual development, protection against late onset sepsis, and a reduction in the incidence of NEC. 
There is now a general consensus that for stable preterm infants, oral feeds should be started on 
day 1.[21] Similar recommendations are being made for the sick preterm, though 
understandably, there is still a cautious approach among the neonatologists with concerns of 
Necrotising Enterocolitis (NEC). 
 
It has been shown in RCTs that advancing feeds at the higher rate of 30 - 35ml/kg/day as 
compared to the traditional lower rate of 15-20mls/kg/day is safe and has the added benefit of 
earlier attainment of birth weight with no increase in the incidence of NEC.[22,23] NEC is the 
main reason for the cautious approach taken to feeding the sick and less stable preterms and the 
reason for the cautious approach in feed advancement as captured in a recent survey of NICU 















advancement is safe, more than 80% of respondents increased feedings at rates of 10 to 20 
mL/kg per day across all weight categories. It is known that the infants at highest risk of 
developing necrotising enterocolitis (NEC) are those born preterm, those with growth 
retardation, those with poor blood flow in utero and unstable infants on ionotropes. 
In a recent Cochrane review,[25] the trials analysed  provided no evidence that delayed 
introduction of progressive enteral feeds affected the incidence of necrotising enterocolitis, 
mortality or other neonatal morbidities. In view of the small number of participants, important 
beneficial or harmful effects could not be excluded. Furthermore, the total number of 115 (very 
few of whom were ELBW) in this trial was small and cannot be used to guide clinical practice. It 
was the authors‘ conclusion that further large pragmatic randomised controlled trials are needed 
to determine how the timing of the introduction of progressive enteral feeds affects important 
clinical outcomes. Unfortunately, this lack of properly designed and executed randomized 
control trials still prevents us from making firm recommendations on the feeding dilemmas in the 
high risk preterms. Retrospective studies, however, have raised concerns that early enteral 
nutrition of preterm infants may lead to an increased risk of NEC.[26] Most prospective, 
randomized trials show that initiating enteral nutrition within the first 3 days of life compared 
with a more delayed introduction improves time to reaching full enteral nutrition and improves 
weight gain.[27-29] Other potential benefits include decreased incidence of osteopenia, 
decreased need for central venous catheters, decreased cholestasis, and decreased incidence of 
sepsis.[30-32] None of these studies showed an increased risk of NEC. Delays in the introduction 
of enteral nutrition often are intertwined with the controversy regarding the safety of enteral 
nutrition when an umbilical artery catheter (UAC) is in place. The presence of a catheter in the 















seem to be affected by the presence of a UAC. Several studies show no association between the 
incidence of NEC and early feedings with a UAC in place.[27, 33] 
A recently concluded large multicentre study in Britain looking at early versus late initiation of 
enteral feeds to growth restricted babies born after abnormal antenatal Doppler is yet to have its 
results published. The Abnormal Doppler Enteral Prescription Trial (ADEPT) is likely to shed 
light as to how to optimally feed the high risk preterm.[34] There is consensus however, that 
implementing a standard feeding protocol in the unit will in itself help in optimizing growth and 
minimizing incidences of NEC.[35] 
Benefits of early enteral feeds and use of breast milk 
After birth there is rapid colonization of the baby‘s gut with a variety of microbial species setting 
up the beginning of a cross talk between the gut and its microflora with implications for immune, 
inflammatory and allergic responses. Babies b rn vaginally tend to have their guts colonized 
earlier than those born via cesarean section as they are exposed to maternal vaginal and colonic 
flora during delivery. Some bacteria are almost always pathogenic, such as clostridia, 
pseudomonas, staphylococcus and proteus. Others can be either pathogenic or beneficial, such as 
Escherichia coli, Bacteroides and Enterobacteriae. Others are thought to be primarily beneficial, 
most commonly Lactobacillus and Bifidobacterium species.[36] 
With the increasing population of the facultative anaerobes in the gut such as Enterobacteriae, 
Enterococci, and Staphylococci, oxygen is consumed allowing for colonization by anaerobic 
bacteria. Thereafter colonization is influenced by feeding, with bacteria introduced via breast 
milk or formula feeds along with factors, particularly in breast milk, which influence 















flora. This ultimately leads to the complete adult colonization by 2 years of age with 400-1000 
different species and a stable pattern that is unique to each individual. 
The gut has an elaborate defense system designed to limit the bacteria to the intestinal lumen. 
This includes peristalsis, gastric acid, proteolytic enzymes, intestinal mucus, cell surface 
glycoconjugates, and tight junctions between intestinal epithelial cells. There is in addition, 
intestinal T and B lymphocytes, sIgA, human defensins secreted by the Paneth cells, and 
intestinal trefoil factor secreted by the intestinal epithelium itself. These will limit the growth of 
bacteria that managed to breech the physical barrier. 
Three cell types – the M cells, the surface enterocytes and the dendritic cells – interact with the 
intestinal microflora tolerating commensal bacteria, while triggering inflammatory responses for 
pathogenic bacteria.  
M cells are found throughout the digestive tract in the specialized follicle associated epithelium 
of mucosal lymphoid follicles or Peyer‘s patches. They transport bacteria to the subepithelial 
dendritic cells via endocytosis, pinocytosis or phagocytosis. 
Surface enterocytes recognize bacteria via Toll-like receptor (TLR). Bacterial attachment to the 
TLR leads to activation of nuclear factor kappaB (NF-ĸB), which in turn activates transcription 
of genes including cytokines such as IL-6 and TNFα, chemokines such as IL-8, adhesion 
molecules, and regulators of apoptosis. 
Antigens from either food or bacteria that come into contact with the intestinal epithelium are 
presented by dendritic cells in the contest of MHC class II molecules to naïve T lymphocytes in 
the peyers‘s patches, with resultant either T helper type 1 (Th1) of T helper type 2 (Th2) 















inappropriate Th2 responses are associated with allergy, thus the association of early feeds with 
autoimmune disease and allergy later in life. 
Healthy term infants staying with their mothers and breastfeeding will acquire genetically 
compatible microbiota which improves nutrition and fortifies gut‘s epithelial barrier.[38] On the 
other hand, abnormal gut flora will increase the incidence of late onset sepsis and NEC. Factors 
which lead to abnormal gut colonization include birth by cesarean section, hygiene practices, 
prolonged antibiotic administration, reduced bowel motility, immature epithelial host defenses, 
type or mode of nutrition, and parenteral nutrition. Needless to say, our very low birth weight 
and ELBW preterms, the bulk of whom are born via emergency cesarean section for maternal 
reasons like elampsia and pre-eclampsia,  snuggly fit into this risk category for abnormal gut 
colonization. 
 
Studies have demonstrated many beneficial effects of the intestinal flora. Bacteria are 
responsible for the provision of essential nutrients such as vitamin k, vitamin B12, and short 
chained fatty acids such as butyrate. Bacteria are important for the metabolism of 
polysaccharides saving the host from expending energy for this process. Through competitive 
colonization, nonpathogenic bacteria reduce colonization of the gut by the pathogenic bacteria. 
Certain bacteria such as E. Coli, Streptococcus thermophilus, Lactobacillus, and Bifidobacterium 
protect against cell death associated with pathogenic bacteria. Commensal bacteria interact with 
the paneth cells promoting the development, maintenance and repair of the intestinal villus. The 
intestinal flora is also responsible for the maturation of the gut with improvement of its 
absorptive function. It has been demonstrated that the intestinal barrier function is compromised 















colonization with commensal bacteria such as E. Coli, Streptococcus thermophilus, Lactobacillus 
and Bifidobacterium.[39] 
 
In the recent past, there has been increasing excitement with the discovery of more and more 
beneficial and bioactive components in breast milk.[40] Many benefits of breast milk to the 
preterm have been elucidated including improved defense against infection, better nutrient 
absorption, reduction in the incidences of NEC and sepsis, gut priming, promotion of 
physiological and endocrine functions of the gut, gut growth and better long term immunity and 
neurodevelopment.[41-45] It is known that human breast milk contains prebiotics and probiotics 
and promotes appropriate initial gut colonization with beneficial bacteria at the expense of 
pathogenic bacteria. Breast milk also selectively nourishes the beneficial intestinal microbiota at 
the expense of the pathogenic bacteria with its many prebiotics. It is speculated that proper gut 
colonization and establishment of a balanced microbiome in the preterms‘ gut is associated with 
the many beneficial effects observed in the breast milk fed babies. 
 
SUMMARY 
1. The recommendations on feeding the ELBW preterm may be summarized as initiation of 
parenteral nutrition on day 1 of life, optimizing caloric and protein intake with 
concomitant early initiation of enteral feeds.  
2. The target growth velocity for the ELBW preterm is 15g/kg/day, which aims at 















3. Post natal growth velocity is an important and independent risk factor for later 
neurodevelopmental outcomes in ELBW preterm babies.  
4. Protein and caloric intakes have the greatest influence on the growth velocity in this 
group of babies. The benefits and safety of early enteral feeds and of breast milk are now 
well established.  
 
GAPS FOR RESEARCH 
Due to resource constraints, our feeding practice deviates from current recommendations. There 
is a need to document how ELBW preterm babies in our unit grow given our feeding practice 
which encourages early enteral feeds with breast milk with supplemental intravenous dextrose 
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Introduction: There is wide variation in the feeding practices of extreme low birth weight 
(ELBW) preterms often guided by tradition and resources. The feeding regimen at Groote 
Schuur Hospital (GSH) nursery, a tertiary neonatal unit, follows a restricted use of parenteral 
nutrition and concentrates on early introduction of breast milk. There is a need to determine if 
this approach achieves acceptable growth velocity. 
Objectives: This study aims to describe the growth velocity of ELBW babies at GSH. 
Design: This was a retrospective cohort study.   
Methodology: Infant hospital records of all ELBW born at GSH from 1
st
 March to 31
st
 August 
2010 were accessed from a previously collected database and relevant data extracted. Growth 
data was collected from birth to 8 weeks post natal age or discharge, whichever came first. 
Results: Ninety one ELBW babies were born during the study period. Forty were excluded from 
the study. Thirty died before discharge and 10 were excluded for other reasons. The mean (SD) 
gestation of the cohort was 28.5 (1.6) weeks and the median (range) birth weight was 875(640 to 
995)g. The overall mean (SD) growth velocity was 14 (2.9) g/kg/day. There was no statistically 
significant association between the growth velocity and the type of feed given, days to 
establishing full enteral feeds, time to regaining birth weight, HIV exposure status, intra-uterine 
growth restriction or exposure to antenatal steroids. 
Conclusion: In our cohort of ELBW infants, growth velocity was within the range currently 

















There has been improved survival of extremely low birth weight (ELBW) infants in recent 
times.[1] With this came the challenge of supplying nutrients to these infants to match their in 
utero accretion rates. There is a wide variation in feeding practices across nurseries primarily 
guided by tradition and available resources.[2,3] In utero, the fetus grows at approximately 
16g/kg/day as from 23 to 37 weeks gestation.[4] This forms the basis for the current American 
Academy of Pediatrics (AAP) recommended target growth rate of 15g/kg/day for the ELBW 
preterm.[5] 
The low protein and caloric content of breast milk leading to the need for unfeasibly large enteral 
volumes together with gut immaturity prevalent in ELBW infants in the first days of life forms 
the rationale for early parenteral nutrition. However, early establishment of full enteral feeds has 
been associated with better postnatal growth.[6-8] Due to limited resources and capacity, our 
practice involves early initiation of enteral feeds with expressed breast milk where feasible, with 
progressive advancement of these feeds and concomitant use of intravenous dextrose enriched 
with electrolytes. Parenteral nutrition is reserved for the infants unable to tolerate enteral feeds. 
This study aims to describe the growth velocity of our cohort of ELBW infants and to compare 
this with internationally acceptable benchmarks. 
















The study was carried out in the tertiary neonatal unit at Groote Schuur Hospital in Cape Town 
South Africa. This 75-bed unit admits approximately 2000 babies every year, 10% of whom are 
ELBW.  
Study population 
This was a retrospective cohort study. Patients were identified from a previously collected 
database of ELBW preterms. All ELBW babies born and admitted into Groote Schuur Hospital‘s 
neonatal intensive care (NICU) from 1
st
 March to 31
st
 Aug 2010 who met the eligibility criteria 
and survived to discharge were included into the study.  
We excluded babies with the following abnormalities: major congenital malformations, 
necrotizing enterocolitis Bell stage II or greater, grade 3 or 4 intraventricular haemorrages or 
periventricular leucomalacia (PVL).  
The following data were collected by chart review: Demographic data, weekly weights, head 
circumference, type of feed, days to full feeds, days to regaining birth weight, exposure to HIV 
and antenatal exposure to steroids. Data were recorded for the period from birth to day 56 of life 
or discharge, whichever came first.  
Statistics 
Data were analyzed using Stata software version 11 (Statacorp, College Station, Texas, USA). 
Parametric data were expressed as mean (standard deviation) while non-parametric data were 
expressed as median (range). The two-tailed student t-test and analysis of variance (ANOVA) 















Categorical data were analyzed with the Chi-square test. Statistical significance was assumed at 
p<0.05. 
Weight measurements 
Babies were weighed between 5am and 6am everyday when in the intensive, high care and 
medium care areas, and three times a week when in the general wards. Unstable patients were 
weighed less frequently. Babies were weighed on digital weighing machines (Seca, Hamburg, 
Germany) that are routinely calibrated. Weekly weights from day 7 to day 56 were retrieved 
from the weight charts in the patient folders and any missing weights were calculated from the 
average of the immediate weight before and after the weight in question. 
Gestational Age estimation 
The gestational age was extrapolated from the antenatal ultrasound report if it was done at less 
than 20 weeks gestation and where this was not available or was uncertain, the Ballard score[9] 
from the infant records was used. 
Growth Velocity Calculations 
Growth velocity (GV) was determined from weekly weights starting from day seven (as 
at this point, weight loss usually has reached its nadir) using the two point system[10] as 
shown below: 
 GV =         [1000 x (Wn – W1)] 
















W – weight in grams, D – day, 1 –beginning of time interval, n – end of time interval in 
days. 
The calculated weekly growth velocities for the first 8 weeks or to discharge (whichever 
came first) were averaged to give the mean growth velocity of the individual baby. 
Increase in head circumference was determined by dividing the gain on the head 
circumference at discharge from that at birth by the duration of stay in weeks. 
Study definitions 
Full enteral feeds was defined as total enteral feeds of 150ml/kg/day which gives a total 
calorie of 100kcal/kg/day estimated from breast milk intake which gives 67 kcal/100mls. 
Time to regain birth weight was defined as the day birth weight was regained and 
sustained (or exceeded) for two consecutive days. The type of feed was defined as the 
predominant feed received in the first 4 weeks. Small for gestational age babies were 
defined as babies that fell below the 10
th
 percentile for birth weight on the Lubchenco 
growth charts.[11] 
Nutritional Practices 
Intravenous fluids were commenced on day 1 at 80-100mls/kg/day with an electrolyte enriched 
5% or 10% dextrose solution depending on blood glucose levels. Enteral feeds were usually 
started on day 2 of life at 10-20mls/kg/day. The feeds were increased by 20mls-35mls/kg every 
day. Intravenous fluids were decreased appropriately to achieve the prescribed total fluid intake 
which increased by 10 to 20mls/kg/day until a total fluid intake of 150mls/kg/day was achieved. 















35mls/kg/day to a maximum of 200mls/kg for breast milk and 160-180mls/kg/day for formula 
feeds.  
The enteral feeds of choice in order of preference were mother‘s own breast milk (pasteurized 
for HIV positive mothers), donated breast milk (pasteurized breast milk from screened donor 
mothers) or preterm formula. 
On attainment of full feeds, those on breast milk feeds had their feeds fortified with a breast milk 
fortifier - FM85
®
 (Nestlé Nutrition) at 1g per 20mls and received additional multivitamin drops 
at 0.3mls daily to discharge. All infants less than 32 weeks corrected gestation received 
additional oral supplementation of sodium chloride at 2 to 3 mmol per day till 32 weeks 
corrected gestational age. Iron supplements were given to all infants as from 2 weeks of age at 2-
4mg/ kg /day to discharge. Oral phosphate at 0.5 to 1 mmol was added from 4 to 6 weeks and the 
dose titrated according to the serum calcium, phosphate and alkaline phosphate levels. 
 
RESULTS 
Figure 1 shows how the study population was derived. Ninety one babies weighing less than 





 Aug 2010). Forty were excluded from the study – 30 died before discharge, two 
were transferred out before regaining birth weight, two had hydrocephalus, one had congenital 
cytomegalovirus (CMV) infection and one had PVL. Four files were not available for analysis, 
leaving a total study population of 51. 















The median birth weight of the cohort was 875(640g-995)g. The mean gestation of the cohort 
was 28.5 (1.6) weeks. The overall mean growth velocity for the entire cohort was 14.0 (2.9) 
g/kg/day, while the mean increase in head circumference was 0.73 (0.37)cm per week. 
The median duration of admission was 55 (36-93) days while the median discharge weight was 
1620 (1540-2080) g. The median duration to achieving full feeds was 7 (6-12) days, while the 
median number of days to regaining birth weight was 15 (1-28). 
Table 2 shows the relationship between growth velocity and other variables. 
There was no statistically significant variation in the mean growth velocity with respect to the 
presence of growth restriction, type of feed, sex, HIV exposure or exposure to antenatal steroids.  
Table 3 shows the results of a logistic regression analysis corrected for sex, looking at predictors 
of a higher growth velocity in our cohort. That is, a growth velocity greater than the cohort‘s 





















The growth velocity of our study population of 14g/kg/day approximates the target growth as 
recommended by the AAP of 15g/kg/day.[5] Despite lack of parenteral nutrition in the first days 
of life in our cohort, the overall GV is similar to those reported in current literature.[2,12-14] 
This could be attributed to the rapid achievement of full enteral feeds in our cohort - median of 
day 7(6-12), indicating that half of our cohort received a total caloric intake from breast milk of 
50kcal/kg by day 3 and 100kcal/kg by day 7. In comparison, Diekman et al [13] reported the 
mean (SD) duration to achieving at least 100kcal/kg/day as day 10.4(4.9) while Donovan[8] 
reported the mean time to full feeds as day of life 12.7(8.6). Olsen and colleagues[2] 
investigating the possible contributors to the differences in growth velocities seen in 6 different 
level 3 neonatal intensive care units reported that none of the 6 NICUs had achieved a mean 
caloric intake of 100kcal/kg/day by day 7 and only two had achieved or surpassed this target by 
the 14
th
 day of life. This study also identified caloric and protein intake as the most significant 
contributors to the differences in growth velocities. Benefits to our cohort may have resulted 
from early maturation and adaptation of the gut by the early introduction of enteral feeds. It has 
previously been shown that early enteral feeds promote intestinal villi growth, development, and 
improve their absorptive and endocrine function.[15] 
Olsen et al[2] calculated growth velocity of their cohort by subtracting the weight on day 3 from 
that of day 28 and dividing this by the number of days (25) and the birth weight. The mean 
growth velocities of the six NICUs they studied were 14.7, 12.5, 12.0, 9.4, 11.2 and 8.6 /kg/day. 
Early parenteral nutrition was used in all the six nurseries. Diekman et al[13] reported a mean 
growth velocity of 15g/kg/day in a cohort of 163 ELBW infants. Their feeding protocol involved 















advancement of the enteral feeds. This was a cohort similar to ours in terms of the weight 
distribution and enteral feeding practice other than for the early use of parenteral nutrition. 
Caution is however advised in comparing the growth velocities because of the different methods 
of calculation in use.[16] For instance, Martin et al[17] reporting on the growth velocity of a 
recent large cohort of ELBW preterms with early initiation of enteral feeds reported a mean 
growth velocity of 18.3g/kg/day when the two point method was used with the day 7 weight as 
the denominator, and 11g/kg/day when birth weight was used as the denominator. The 
exponential equation, which has been shown to be the most accurate[16] gave a mean growth 
velocity of 15.5g/kg/day for the same cohort. 
Our cohort‘s mean growth in head circumference of 0.7cm per week is comparable to that 
reported by Ehrenkranz and colleagues.[12] This is assuring given the established strong 
association between postnatal head growth and later neurodevelopmental outcomes.[18-19] 
A logistic regression analysis exploring the risk factors for a growth rate higher than 14g/kg/day 
did not identify any statistically significant risks in our cohort. Time to establishing full feeds 
and state of being small for gestational age have both been repeatedly shown in previous studies 
to be positive influences on the growth velocity.[7,12,13] It is likely that our small sample size 
lacked the power to show these differences. 
CONCLUSION 
In our resource constrained setting, early enteral feeding of extremely low birth weight preterms 
with breast milk with concomitant administration of intravenous dextrose enriched with 
electrolytes until the establishment of full enteral feeds is associated with a mean growth velocity 















early establishment of enteral feeds. There is need for studies to assess the possibility and 
benefits of more rapid advancement of enteral feeds in ELBW preterms. This may further cut 
down on the early nutrient deficit and improve growth velocity in this group of neonates.  
WHAT IS ALREADY KNOWN ON THIS TOPIC 
Initiation of parenteral nutrition on day 1 of life, optimizing caloric and protein intake with 
concomitant early initiation of enteral feeds forms the current recommendation in feeding the 
ELBW preterm.  
The current recommended target growth velocity for the ELBW preterm is 15g/kg/day. 
Post natal growth velocity is an important and independent risk factor for later 
neurodevelopmental outcomes in ELBW preterm babies. 
WHAT THIS STUDY ADDS 
This study shows how the growth velocity of ELBW preterms in a resource constrained setting 
receiving early enteral feeds without parenteral nutrition is similar to that of their counterparts in 
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Table 1: Baseline characteristics 
Characteristics Number (%) 
Male Sex  22 (43) 
Small for Gestational Age  23 (45) 
HIV Exposed 19 (37) 
Antenatal steroids received                         37 (72) 
Surfactant given 21 (41) 
Normal Vaginal Delivery 9 (18) 
Cesarean Section 42 (82) 
Antenatal pre-eclamptic toxaemia 36 (70) 
Unexplained preterm labor 10 (20) 
Infants on expressed breast milk 30 (59) 
Infants on DEBM 12 (23) 
Infants on PEBM 8 (16) 
Infants on formula feeds 1 (2) 
 















Table 2: Relationship between growth velocity and other variables 
Factor  No. Mean GV Test P- value 
Type of feed EBM 30 14.3 ANOVA 0.09 
 DEBM 12 13.8   
 PEBM 8 12.9   
HIV exposure Exposed  19 13.6 T Test 0.46 
 Not exposed 32 14.2   
Antenatal Steroids Received 37 14.6 T Test 0.30 
 Not received 14 13.7   
Appropriateness of weight for age SGA 23 14.3 T Test 0.52 
 AGA 28 13.7   
Gender Male 22 13.1 T Test 0.05 
 Female 29 14.7   
 
EBM – expressed breast milk; DEBM – Donated expressed breast milk; PEBM – Pasteurized 
















Table 3: logistic regression analysis examining the predictors of appropriate growth 
velocity 
Factor  Total GV > 14  O.R. 95% C.I. 
No % 
Type of feed EBM 30 18 60.0 1 Ref 
 DEBM 12 6 50.0 0.7 0.2 – 2.7 
 PEBM 8 3 37.5 0.4 0.1 – 2.0 
Appropriateness for GA SGA 23 13 56.5 1.3 0.4 – 4.1 
HIV Exposure Exposed 19 10 52.6 1.0 0.3 – 3.3 
Antenatal Steroids Received 37 19 51.4 0.9 0.3 – 3.4 
Days to achieving full feeds Less than 8 days 31 19 61.3 2.2 0.7 – 7.2 
Days to regaining birth weight Less than 15 days 28 15 50 0.8 0.3 – 2.5 
 
EBM – expressed breast milk; DEBM – Donated expressed breast milk; PEBM – Pasteurized 
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 Exploration of variables: 
Variable  Obs Mean  Std. Dev Min Max median 
 Duration of adm 51 57.60  13.247  36 93 54 
Gestation  51 28.60  1.6257  26 33 28 
 Head growth  48 0.72  0.3679  0.3 2.9 0.7 
Birth weight  51 858.21  100.70  640 995 870 
Weight gain/kg/d 51 13.98  2.9282  6.16 19.73 14.1 
 Discharge weight 50 1675.8  138.07  1540 2080 1630 
 Days to full feeds 51 7.33  1.2596  6 12 7 
 Days to Bwt  51 14.11  5.7189  1 28 15 
 
Shapiro-Wilk W test for normal data 
 
    Variable    Obs W V  z  Prob>z 
------------------------------------------------------------------------------------------------- 
Duration of admission 51 0.94 2.414  1.882  0.029 
Gestation   51 0.95 2.204  1.688  0.045 
 Head growth   48 0.58 18.761  6.237  0.000 
 Birth weight   51 0.94 2.446  1.909  0.028 
 Weight gain (wt/kg/d) 51 0.98 0.611  -1.050  0.853 
 Discharge weight  50     0.79 9.446   4.789  0.000 
 Days to full feeds  51 0.90 4.410  3.168  0.000 
Days to birth weight  51 0.98 0.558  -1.248  0.893 
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